Translational Research

The Side-Out Foundation is sponsoring a first of its kind clinical trial to examine the effects of individualized treatment on patients with metastatic breast cancer. Individualized treatment, known as targeted therapy, provides doctors a better way to tailor cancer treatment and offers the hope of more precisely targeting the cancerous cells, which would reduce side effects and improve quality of life.

The trial protocol has brought together the diverse skills and unique experience of community oncologists, nurses and researchers in the field molecular medicine. Translational Genomics Research Institute (TGen) Drug Development Services (TD2) will manage the trial for The Side-Out Foundation.

Researchers will utilize these advanced molecular profiling technologies, focusing on tailoring therapy for each patient based on the individual genomic and proteomic molecular portrait within the metastatic lesion itself. The patient would then be treated with a single agent based on the aggregate information provided by the genomic and proteomic molecular profiling analyses.

In 2015, Side-Out was honored to be awarded the PhRMA Community Champion Research & Hope Award.

For more information about the Side-Out Protocol, visit or contact Bryant Dunetz. Click below for details about the results of Side-Out 1 and Side-Out 2.

Side-Out 1
Side-Out 2

Trial Locations Supporting Laboratories
Mayo Clinic(Scottsdale, AZ) Translational Genomics Research Institute (TGen)
Virginia Cancer Specialists (Fairfax, VA) Caris Life Sciences
University of Miami(Miami, FL) George Mason University’s Center for Applied Proteomics and Molecular Medicine (CAPMM)
Arizona Oncology Sedona (Sedona, AZ) Paradigm